• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

KMSubtraction:利用已发表的 Kaplan-Meier 生存曲线重建未报告亚组生存数据。

KMSubtraction: reconstruction of unreported subgroup survival data utilizing published Kaplan-Meier survival curves.

机构信息

Yong Loo Lin School of Medicine, National University of Singapore, 21 Lower Kent Ridge Rd, Singapore, 119077, Singapore.

Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.

出版信息

BMC Med Res Methodol. 2022 Apr 3;22(1):93. doi: 10.1186/s12874-022-01567-z.

DOI:10.1186/s12874-022-01567-z
PMID:35369867
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8978435/
Abstract

BACKGROUND

Data from certain subgroups of clinical interest may not be presented in primary manuscripts or conference abstract presentations. In an effort to enable secondary data analyses, we propose a workflow to retrieve unreported subgroup survival data from published Kaplan-Meier (KM) plots.

METHODS

We developed KMSubtraction, an R-package that retrieves patients from unreported subgroups by matching participants on KM plots of the overall cohort to participants on KM plots of a known subgroup with follow-up time. By excluding matched patients, the opposing unreported subgroup may be retrieved. Reproducibility and limits of error of the KMSubtraction workflow were assessed by comparing unmatched patients against the original survival data of subgroups from published datasets and simulations. Monte Carlo simulations were utilized to evaluate the limits of error of KMSubtraction.

RESULTS

The validation exercise found no material systematic error and demonstrates the robustness of KMSubtraction in deriving unreported subgroup survival data. Limits of error were small and negligible on marginal Cox proportional hazard models comparing reconstructed and original survival data of unreported subgroups. Extensive Monte Carlo simulations demonstrate that datasets with high reported subgroup proportion (r = 0.467, p < 0.001), small dataset size (r = - 0.374, p < 0.001) and high proportion of missing data in the unreported subgroup (r = 0.553, p < 0.001) were associated with uncertainty are likely to yield high limits of error with KMSubtraction.

CONCLUSION

KMSubtraction demonstrates robustness in deriving survival data from unreported subgroups. The limits of error of KMSubtraction derived from converged Monte Carlo simulations may guide the interpretation of reconstructed survival data of unreported subgroups.

摘要

背景

某些具有临床意义的亚组数据可能未在主要手稿或会议摘要报告中呈现。为了能够进行二次数据分析,我们提出了一种从已发表的 Kaplan-Meier(KM)图中检索未报告亚组生存数据的工作流程。

方法

我们开发了 KMSubtraction,这是一个 R 包,通过在总体队列的 KM 图上匹配参与者与已知亚组的 KM 图上的参与者(具有随访时间),从未报告的亚组中检索患者。通过排除匹配的患者,可以检索到相反的未报告亚组。通过将未匹配的患者与已发表数据集和模拟中的亚组原始生存数据进行比较,评估 KMSubtraction 工作流程的重现性和误差限制。利用蒙特卡罗模拟评估 KMSubtraction 的误差限制。

结果

验证实验未发现明显的系统误差,并证明了 KMSubtraction 在推导出未报告亚组生存数据方面的稳健性。在比较重建和未报告亚组的原始生存数据的边缘 Cox 比例风险模型中,误差限制很小且可以忽略不计。广泛的蒙特卡罗模拟表明,具有高报告亚组比例(r = 0.467,p < 0.001)、小数据集大小(r = -0.374,p < 0.001)和未报告亚组中高缺失数据比例(r = 0.553,p < 0.001)的数据集可能会产生不确定性,使用 KMSubtraction 会产生较高的误差限制。

结论

KMSubtraction 在从未报告亚组中推导出生存数据方面表现出稳健性。从收敛的蒙特卡罗模拟中得出的 KMSubtraction 的误差限制可以指导对未报告亚组的重建生存数据的解释。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c3d/8978435/e980e51dcc8f/12874_2022_1567_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c3d/8978435/f3f9b92f3fc8/12874_2022_1567_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c3d/8978435/77b6218c556c/12874_2022_1567_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c3d/8978435/bbee1a986a9c/12874_2022_1567_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c3d/8978435/5b744bed0ca9/12874_2022_1567_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c3d/8978435/e980e51dcc8f/12874_2022_1567_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c3d/8978435/f3f9b92f3fc8/12874_2022_1567_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c3d/8978435/77b6218c556c/12874_2022_1567_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c3d/8978435/bbee1a986a9c/12874_2022_1567_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c3d/8978435/5b744bed0ca9/12874_2022_1567_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c3d/8978435/e980e51dcc8f/12874_2022_1567_Fig5_HTML.jpg

相似文献

1
KMSubtraction: reconstruction of unreported subgroup survival data utilizing published Kaplan-Meier survival curves.KMSubtraction:利用已发表的 Kaplan-Meier 生存曲线重建未报告亚组生存数据。
BMC Med Res Methodol. 2022 Apr 3;22(1):93. doi: 10.1186/s12874-022-01567-z.
2
Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma.低程序性死亡配体1表达亚组在胃或食管腺癌一线免疫检查点抑制剂治疗中的结局
J Clin Oncol. 2022 Feb 1;40(4):392-402. doi: 10.1200/JCO.21.01862. Epub 2021 Dec 3.
3
IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves.KM-IPD: 从已发表的 Kaplan-Meier 生存曲线中重建个体患者数据。
BMC Med Res Methodol. 2021 Jun 1;21(1):111. doi: 10.1186/s12874-021-01308-8.
4
Efficacy of Oral SERDs in the treatment of ER+, HER2 - metastatic breast cancer, a stratified analysis of the ESR1 wild type and mutant subgroups.口服SERD类药物治疗雌激素受体阳性、人表皮生长因子受体2阴性转移性乳腺癌的疗效:ESR1野生型和突变亚组的分层分析
Ann Oncol. 2023 Oct 21. doi: 10.1016/j.annonc.2023.10.122.
5
Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves.增强型生存数据分析:从已发表的 Kaplan-Meier 生存曲线中重建数据。
BMC Med Res Methodol. 2012 Feb 1;12:9. doi: 10.1186/1471-2288-12-9.
6
A non-linear optimisation method to extract summary statistics from Kaplan-Meier survival plots using the published P value.一种使用已发表的 P 值从 Kaplan-Meier 生存图中提取汇总统计量的非线性优化方法。
BMC Med Res Methodol. 2020 Oct 30;20(1):269. doi: 10.1186/s12874-020-01092-x.
7
Estimating hazard ratios from published Kaplan-Meier survival curves: A methods validation study.从发表的 Kaplan-Meier 生存曲线估计风险比:方法验证研究。
Res Synth Methods. 2019 Sep;10(3):465-475. doi: 10.1002/jrsm.1362. Epub 2019 Jun 24.
8
Identification of a gene expression signature predicting survival in oral cavity squamous cell carcinoma using Monte Carlo cross validation.利用蒙特卡罗交叉验证鉴定预测口腔鳞状细胞癌生存的基因表达特征。
Oral Oncol. 2018 Mar;78:72-79. doi: 10.1016/j.oraloncology.2018.01.012. Epub 2018 Feb 20.
9
Assessment of gastric cancer survival: using an artificial hierarchical neural network.胃癌生存率评估:使用人工分层神经网络
Pak J Biol Sci. 2008 Apr 15;11(8):1076-84. doi: 10.3923/pjbs.2008.1076.1084.
10
Visualizing Time-Varying Effect in Survival Analysis: 5 Complementary Plots to Kaplan-Meier Curve.生存分析中时变效应的可视化:与 Kaplan-Meier 曲线互补的 5 个图。
Oxid Med Cell Longev. 2022 Mar 29;2022:3934901. doi: 10.1155/2022/3934901. eCollection 2022.

引用本文的文献

1
Reconstructing patient level survival data from published Kaplan-Meier curves.从已发表的Kaplan-Meier曲线重建患者层面的生存数据。
Contemp Clin Trials Commun. 2025 Aug 20;47:101542. doi: 10.1016/j.conctc.2025.101542. eCollection 2025 Oct.
2
Cost-effectiveness analysis of sugemalimab combined with chemotherapy as first-line treatment for advanced gastric cancer.苏金单抗联合化疗作为晚期胃癌一线治疗的成本效益分析。
Front Public Health. 2025 Jul 31;13:1620663. doi: 10.3389/fpubh.2025.1620663. eCollection 2025.
3
PD-L1 expression predicts the efficacy of PD-1 blockade plus chemotherapy versus chemotherapy alone in treatment-naïve advanced or metastatic gastric cancer: a pooled analysis of reconstructed individual patient-level data from two randomized trials.

本文引用的文献

1
Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma.低程序性死亡配体1表达亚组在胃或食管腺癌一线免疫检查点抑制剂治疗中的结局
J Clin Oncol. 2022 Feb 1;40(4):392-402. doi: 10.1200/JCO.21.01862. Epub 2021 Dec 3.
2
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.帕博利珠单抗联合化疗与单纯化疗一线治疗晚期食管癌(KEYNOTE-590):一项随机、安慰剂对照、III 期研究。
Lancet. 2021 Aug 28;398(10302):759-771. doi: 10.1016/S0140-6736(21)01234-4.
3
程序性死亡配体1(PD-L1)表达可预测在未经治疗的晚期或转移性胃癌中,与单纯化疗相比,程序性死亡受体1(PD-1)阻断联合化疗的疗效:一项对两项随机试验重建的个体患者水平数据的汇总分析。
Front Cell Dev Biol. 2025 Jul 3;13:1636288. doi: 10.3389/fcell.2025.1636288. eCollection 2025.
4
Investigating the Synergistic Effects of Pembrolizumab and Chemotherapy in Gastric and Gastroesophageal Junction Cancer.探究帕博利珠单抗与化疗联合治疗胃及胃食管交界癌的协同效应。
J Gastric Cancer. 2025 Jul;25(3):455-465. doi: 10.5230/jgc.2025.25.e33.
5
Comparison of immune checkpoint inhibitors in combination with chemotherapy versus chemotherapy alone in the first-line treatment of advanced gastric cancer patients with low PD-L1 expression: a systematic review and meta-analysis.免疫检查点抑制剂联合化疗与单纯化疗用于一线治疗低PD-L1表达的晚期胃癌患者的比较:一项系统评价和荟萃分析
Ther Adv Med Oncol. 2025 May 8;17:17588359251336627. doi: 10.1177/17588359251336627. eCollection 2025.
6
Construction and Validation of a T Cell Exhaustion-Related Prognostic Signature in Cholangiocarcinoma.胆管癌中T细胞耗竭相关预后标志物的构建与验证
Int J Genomics. 2025 Mar 10;2025:8823837. doi: 10.1155/ijog/8823837. eCollection 2025.
7
Deeper Analysis to Identify the True Benefit of ICIs Immunotherapy in First-Line Treatment for Non-HER2-Positive/HER2-Negative Advanced or Metastatic Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC).深入分析以确定免疫检查点抑制剂(ICIs)免疫疗法在一线治疗非HER2阳性/HER2阴性晚期或转移性胃癌(GC)或胃食管交界癌(GEJC)中的真正益处。
Cancers (Basel). 2025 Feb 15;17(4):657. doi: 10.3390/cancers17040657.
8
Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma: a series of patient-level meta-analyses in different programmed death-ligand 1 subgroups.免疫检查点抑制剂在晚期胃食管腺癌中的应用:不同程序性死亡配体 1 亚组患者水平的一系列荟萃分析。
ESMO Open. 2024 Nov;9(11):103962. doi: 10.1016/j.esmoop.2024.103962. Epub 2024 Oct 18.
9
First-line immune checkpoint inhibitors in low programmed death-ligand 1-expressing population.低程序性死亡配体1表达人群中的一线免疫检查点抑制剂
Front Pharmacol. 2024 Jul 26;15:1377690. doi: 10.3389/fphar.2024.1377690. eCollection 2024.
10
The efficacy of immune checkpoint inhibitors on low PD-L1 cervical cancer: A meta-analysis.免疫检查点抑制剂对低程序性死亡配体1表达宫颈癌的疗效:一项荟萃分析。
Health Sci Rep. 2024 May 2;7(5):e2069. doi: 10.1002/hsr2.2069. eCollection 2024 May.
Intra-Arterial Therapy for Unresectable Colorectal Liver Metastases: A Meta-Analysis.
经动脉治疗不可切除结直肠癌肝转移:一项荟萃分析。
J Vasc Interv Radiol. 2021 Nov;32(11):1536-1545.e38. doi: 10.1016/j.jvir.2021.05.032. Epub 2021 Jun 22.
4
Subgroup Analyses in Oncology Trials: Regulatory Considerations and Case Examples.肿瘤学试验中的亚组分析:监管考虑因素和案例示例。
Clin Cancer Res. 2021 Nov 1;27(21):5753-5756. doi: 10.1158/1078-0432.CCR-20-4912. Epub 2021 Jun 11.
5
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.一线纳武利尤单抗联合化疗与单纯化疗治疗晚期胃癌、胃食管交界癌和食管腺癌(CheckMate 649):一项随机、开放标签的3期试验。
Lancet. 2021 Jul 3;398(10294):27-40. doi: 10.1016/S0140-6736(21)00797-2. Epub 2021 Jun 5.
6
IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves.KM-IPD: 从已发表的 Kaplan-Meier 生存曲线中重建个体患者数据。
BMC Med Res Methodol. 2021 Jun 1;21(1):111. doi: 10.1186/s12874-021-01308-8.
7
Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants.代谢性减重手术与有或无糖尿病成人长期生存的关联:一项对 174772 名参与者的匹配队列和前瞻性对照研究的一阶段荟萃分析。
Lancet. 2021 May 15;397(10287):1830-1841. doi: 10.1016/S0140-6736(21)00591-2. Epub 2021 May 6.
8
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.帕博利珠单抗或帕博利珠单抗联合化疗对比单纯化疗用于一线晚期胃癌患者的疗效和安全性:KEYNOTE-062 期随机临床研究。
JAMA Oncol. 2020 Oct 1;6(10):1571-1580. doi: 10.1001/jamaoncol.2020.3370.
9
Review of precision cancer medicine: Evolution of the treatment paradigm.精准肿瘤医学述评:治疗范式的演变。
Cancer Treat Rev. 2020 Jun;86:102019. doi: 10.1016/j.ctrv.2020.102019. Epub 2020 Mar 31.
10
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.纳武利尤单抗联合伊匹单抗治疗晚期非小细胞肺癌。
N Engl J Med. 2019 Nov 21;381(21):2020-2031. doi: 10.1056/NEJMoa1910231. Epub 2019 Sep 28.